🇺🇸 PT-112 in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 11

Most-reported reactions

1. Pleural Effusion — 2 reports (18.18%)
2. Acute Kidney Injury — 1 report (9.09%)
3. Anaemia — 1 report (9.09%)
4. Brain Natriuretic Peptide Increased — 1 report (9.09%)
5. Dehydration — 1 report (9.09%)
6. Diarrhoea — 1 report (9.09%)
7. Dyspnoea — 1 report (9.09%)
8. Myositis — 1 report (9.09%)
9. Neuropathy Peripheral — 1 report (9.09%)
10. Neutropenia — 1 report (9.09%)

Source database →

Frequently asked questions

Is PT-112 approved in United States?

PT-112 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for PT-112 in United States?

Promontory Therapeutics Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.